Advertisement

Document › Details
Galapagos N.V.. (1/8/19). "Press Release: Sands Capital Reports 5.7% Holding in Galapagos". Mechelen.
Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Sands Capital Management, LLC.
Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 27 December 2018 from Sands Capital Management, LLC, who notified that it held 3,092,264 of Galapagos' voting securities (consisting of American Depository Shares) on 13 September 2018. On this date, Sands Capital Management, LLC, crossed the 5% threshold of Galapagos' voting securities by acquiring additional securities. These 3,092,264 securities represented 6.02% of Galapagos' then outstanding 51,337,763 shares. Since the number of outstanding Galapagos shares currently stands at 54,465,421, the 3,092,264 securities of Sands Capital Management currently represent 5.7%. The full transparency notice is available on the Galapagos website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Contact
Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784
Sofie Van Gijsel
Director IR
+32 485 19 14 15
ir@glpg.com
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.
Record changed: 2019-03-31 |
Advertisement

More documents for Galapagos (Group)
- [1] Galapagos N.V.. (2/10/21). "Press Release: Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF". Foster City, CA & Mechelen....
- [2] Galapagos N.V.. (12/15/20). "Press Release: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (filgotinib)". Foster City, CA & Mechelen....
- [3] Galapagos N.V.. (11/23/20). "Press Release: Selvita to Acquire Fidelta from Galapagos". Mechelen & Krakow....
- [4] Galapagos N.V.. (11/5/20). "Press Release: OncoArendi and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis". Mechelen & Warsaw....
- [5] Galapagos N.V.. (10/15/20). "Press Release: Galapagos and Servier Report Topline Results for ROCCELLA Phase 2 Clinical Trial with GLPG1972/S201086 in Knee Osteoarthritis Patients". Mechelen & Paris....
- [6] Galapagos N.V.. (8/19/20). "Press Release: Galapagos Announces that Gilead Received a Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis". Mechelen....
- [7] Galapagos N.V.. (8/12/20). "Press Release: Scipher Medicine and Galapagos Sign Collaboration in Inflammatory Bowel Disease". Mechelen & Boston, MA....
- [8] Galapagos N.V.. (4/16/20). "Press Release: Galapagos and Ryvu Announce Research Collaboration". Mechelen & Krakow....
- [9] Gilead Sciences, Inc.. (2/4/20). "Press Release: Gilead Sciences Announces Fourth Quarter and Full Year 2019 Financial Results". Foster City, CA....
- [10] Galapagos N.V.. (1/23/20). "Press Release: Galapagos Appoints Michele Manto as Chief Commercial Officer". Mechelen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top